A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

CompletedOBSERVATIONAL

Enrollment

460,558

Participants

Timeline

Start Date

April 2, 2018

Primary Completion Date

November 15, 2018

Study Completion Date

November 15, 2018

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Empagliflozin

Trial Locations (1)

Boehringer Ingelheim AB, Stockholm